Stockscreener 앱 받기
0.8101
2.60%
-0.0216
시간 외 거래:
.82
0.0099
+1.22%
전일 마감가:
$0.8317
열려 있는:
$0.8395
하루 거래량:
2.04M
Relative Volume:
0.71
시가총액:
$317.12M
수익:
$86.26M
순이익/손실:
$-50.08M
주가수익비율:
-3.3079
EPS:
-0.2449
순현금흐름:
$-94.48M
1주 성능:
-8.06%
1개월 성능:
-17.74%
6개월 성능:
-47.74%
1년 성능:
-20.58%
1일 변동 폭
$0.8052
$0.8792
1주일 범위
$0.8052
$0.9351
52주 변동 폭
$0.79
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
명칭
Standard Biotools Inc
전화
(650) 266-6000
주소
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.8101 | 332.12M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-02-27 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | 개시 | TD Cowen | Buy |
| 2024-04-04 | 개시 | Jefferies | Buy |
| 2023-07-12 | 개시 | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc 주식(LAB)의 최신 뉴스
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? - TradingView
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Viking backs Standard BioTools (LAB) merger with Treeline Biosciences - Stock Titan
Casdin funds deepen tie to Standard BioTools (LAB) with 23.9% stake and Treeline merger support - Stock Titan
Company that shut down Peninsula HQ now swept up in reverse merger - The Business Journals
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings - Sahm
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools Inc. (LAB) Discusses Merger and Strategic RationaleSlideshow (NASDAQ:LAB) 2026-06-08 - Seeking Alpha
Standard BioTools (LAB) Plunges Over 30%, Testing Critical Support at $0.76PCR Spike - newsline.com
Standard BioTools and Treeline Biosciences anno... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12 - Minichart
Standard BioTools to Merge with Treeline Biosciences - TipRanks
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal - Stock Titan
Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion - TradingView
Treeline Biosciences, Standard BioTools (NASDAQ: LAB) plan all-stock merger - Stock Titan
Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company - citybiz
Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal - marketscreener.com
Standard BioTools to merge with Treeline Biosciences By Investing.com - Investing.com Nigeria
Standard BioTools to merge with Treeline Biosciences - Investing.com
$900M cancer drug pipeline: Treeline, Standard BioTools to merge - Stock Titan
Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Standard BioTools and Treeline Biosciences Announce Merger Agreement - GlobeNewswire
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools - fenwick.com
Standard BioTools Inc. 8-K Filing Details for June 5, 2026: Company Information, NASDAQ Listing, and Legal Disclosures – Minichart - Minichart
Standard BioTools Regains Nasdaq Minimum Bid Compliance Status - TipRanks
Standard BioTools regains Nasdaq bid-price compliance; matter closed - TradingView
Standard BioTools (NASDAQ: LAB) back in compliance with Nasdaq bid rule - Stock Titan
Standard BioTools Grants RSUs to Chief Business Officer - TipRanks
Standard BioTools (LAB) awards 500,000 RSUs to Chief Business Officer - Stock Titan
Standard BioTools Adopts New Executive Severance Protection Plans - TipRanks
Standard BioToolsapproves 2026 change of control and severance plan on May 21, 2026 - marketscreener.com
Standard BiotoolsApproves 2026 Change Of Control And Severance Plan On May 21, 2026 - TradingView
Standard BioTools CFO Alex Kim and CBO Sean Mackay enter 2026 Severance Plan; CEO Michael Egholm joins 2023 Plan - TradingView
Standard BioTools (LAB) sets new executive and CEO change-of-control severance terms - Stock Titan
Standard Biotools Live Share Prices and Trades. LAB.US Live Streaming Share Prices. - London South East
Standard BioTools shares hold over $1 as Nasdaq deadline nears - Bez Kabli
Standard BioTools (LAB) Hovers Near Support After Modest DeclineBlue Chip Entry Points - The Legal Advocate
Standard BioTools (LAB) Nears Support After Slight Decline Amid Cautious TradingValue Stock Ideas - The Legal Advocate
STANDARD BIOTOOLS (LAB) CFO has 18,871 shares withheld for RSU taxes - Stock Titan
Standard Biotools (LAB) SVP has 25,729 shares withheld for taxes - Stock Titan
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations - Stock Titan
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Fails to Lift Shares Amid Revenue UncertaintyProfit Announcement - Newser
DKSH : and Standard BioTools Announce Distribution Partnership to Expand Spatial Biology and Proteomics Solutions in Australia and New Zealand - marketscreener.com
Standard BioTools (LAB) Q1 2026 Earnings: $0.33 EPS Surges Past $-0.06 EstimatesStock Idea Hub - Newser
Standard BioTools (LAB) Q1 2026 Earnings Surprise: EPS $0.33, Up SignificantCrowd Consensus Signals - Newser
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player - AD HOC NEWS
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools - Stock Titan
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools - Stock Titan
Should You Sell Standard BioTools (LAB) After -1.52% Drop? 2026-05-15Collaborative Trading Signals - Newser
Standard Biotools Inc (LAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Standard Biotools Inc 주식 (LAB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kim Hanjoon Alex | Chief Financial Officer |
Apr 06 '26 |
Option Exercise |
0.00 |
70,183 |
0 |
2,800,702 |
| Casdin Partners Master Fund, L | Director |
Dec 04 '25 |
Buy |
1.45 |
150,000 |
217,020 |
72,100,000 |
| Casdin Partners Master Fund, L | Director |
Dec 02 '25 |
Buy |
1.42 |
125,000 |
177,512 |
71,875,000 |
| Casdin Partners Master Fund, L | Director |
Dec 03 '25 |
Buy |
1.44 |
75,000 |
108,037 |
71,950,000 |
| Casdin Partners Master Fund, L | Director |
Nov 25 '25 |
Buy |
1.30 |
7,550,000 |
9,838,405 |
71,750,000 |
| Casdin Partners Master Fund, L | Director |
Nov 24 '25 |
Buy |
1.43 |
150,000 |
214,875 |
64,200,000 |
| Casdin Partners Master Fund, L | Director |
Nov 20 '25 |
Buy |
1.30 |
450,000 |
586,260 |
64,050,000 |
| Casdin Partners Master Fund, L | Director |
Nov 19 '25 |
Buy |
1.28 |
350,000 |
448,910 |
63,600,000 |
| Casdin Partners Master Fund, L | Director |
Nov 18 '25 |
Buy |
1.23 |
275,000 |
339,405 |
63,250,000 |
| Casdin Partners Master Fund, L | Director |
Nov 13 '25 |
Buy |
1.20 |
450,000 |
541,395 |
62,500,000 |
2.43%
자본화:
|
볼륨(24시간):